Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.

Chedid, L; Parant, M; Parant, F.; Lefrancher, P; Choay, J; Lederer, E.

doi:10.1073/pnas.74.5.2089

Cited by 204 publications

(81 citation statements)

References 21 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were similar to those obtained with other immunostimulatory adjuvants, many of which are TLR agonists (13). Those TLR agonists that have been used as adjuvants include lipopolysaccharide (23), CpG DNA (24,25), muramyl dipeptides (26,27), monophosphoryl lipid A (28), and imiquimod (29,30).…”

Section: Discussionsupporting

confidence: 73%

In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen

Kelly-Scumpia¹,

Nacionales²,

Scumpia³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Many lupus autoantigens contain small, highly structured RNAs, and studies have shown that the RNA components of lupus autoantigens activate production of type I interferon by dendritic cells (DCs) in vitro via the Toll-like receptor (TLR)-myeloid differentiation factor 88 pathway. This study was undertaken to examine whether U1 RNA possesses adjuvant activity in vivo.Methods. U1 RNA was affinity purified from K562 cells. C57BL/6 or OT-II mice were immunized with 4-hydroxy-3-nitrophenyl acetyl (NP)-conjugated keyhole limpet hemocyanin (NP-KLH) or ovalbumin 323-337 peptide, using either U1 RNA or aluminum hydroxide (alum) as the adjuvant. Activation of DCs and lymphocytes was measured using flow cytometry. NP-specific antibody responses were measured using enzyme-linked immunosorbent assay. Antigen-specific T cell proliferation was determined using

show abstract

Section: Discussionsupporting

confidence: 73%

In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen

Kelly-Scumpia¹,

Nacionales²,

Scumpia³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Furthermore, Chedid et al and the others reported that several MDP analogs enhanced host resistance to bacterial infection (11, 13,14,[40][41][42]. The aim of the present report is twofold: to give the results of a detailed study of the augmentation of host resistance to bacterial infection induced by MDP(Ala), and to evaluate the efficacy of MDP analogs in which the L-alanyl residue of MDP(Ala) was replaced with another L-amino acid.…”

mentioning

confidence: 99%

Stimulation of Nonspecific Host Resistance to Infection Induced by Muramyldipeptides

Matsumoto

Ogawa

Nagase

et al. 1981

Microbiology and Immunology

View full text Add to dashboard Cite

The effect of muramyldipeptide (MDP), N-acetylmuramyl-L-alanyl-Disoglutamine [MDP(Ala)], and its analogs on bacterial infection was studied using the experimental model of sepsis infection in mice. Injection of MDP(Ala) gave mice definitive protection against E. coli infection, but only partial protection against P. aeruginosa or K. pneumoniae infection. Several factors influencing the protective activity of MDP(Ala) on E. coli infection were studied, and it was demonstrated that the activity was induced by various routes of administration of MDP(Ala), including the oral route, and was markedly influenced by the bacterial inoculum size. It was also shown that the effective dose of MDP(Ala) was 100 flg per mouse for intraperitoneal, intravenous or subcutaneous injections and 1,000 flg per mouse when administered orally. Furthermore, the optimal interval between MDP-treatment and infection was 24 hr when the treatment was carried out before infection. Clearance of bacterial cells in blood was observed after E. coli infection in mice treated with MDP(Ala).The efficacy of MDP(Ala) and two analogs, N-acetylmuramyl-L-valyl-Disoglutamine [MDP(Val)] and N-acetylmuramyl-L-seryl-D-isoglutamine [MDP (Ser)], was evaluated for the E. coli infection; MDP(Val) was proven to be slightly less active than MDP(Ala), and MDP(Ser) to be the least effective, although MDP(Val) or MDP(Ser) was reported to have higher adjuvanticity than MDP (Ala) for the development of delayed-type hypersensitivity.

show abstract

“…In preliminary experiments, daily administration of 0.3 mg/kg LSN B for five days resulted in a sixfold increase in peripheral neutrophils, but no ( FK-156) and isohematinic acid, which enhance the function of neutrophils and thereby augment host resistance to bacterial infection (4,8,13,18). When the activities of some of these compounds are compared with that of LSN B, in our assay system (18), the effects of LSN B were stronger than those of MDP and isohematinic acid, and comparable with those of human recombinant G-CSF (data not shown).…”

Section: Discussionmentioning

confidence: 99%

Augmentation of Host Resistance against Bacterial Infection by Treatment with Leustroducsin B, a New CSF Inducer

Kohama

Katayama²,

Inukai³

et al. 1994

Microbiology and Immunology

View full text Add to dashboard Cite

We tested the in vivo activity of leustroducsin B (LSN B), a new colony-stimulating factor (CSF) inducer isolated from the culture broth of Streptomyces platensis, with mice infected with Escherichia coli. Treatment with LSN B augmented the host resistance to lethal infection of E. coli at doses between 0.1 mg/kg and 1 mg/kg. Serum interleukin-6 (IL-6) levels were found to increase after this treatment, and superoxide anion generation of neutrophils was enhanced in vivo, suggesting that LSN B augmented the host resistance at least in part by inducing IL-6, which subsequently enhanced the bactericidal activity of the neutrophils.

show abstract

Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.

Cited by 204 publications

References 21 publications

In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen

In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen

Stimulation of Nonspecific Host Resistance to Infection Induced by Muramyldipeptides

Augmentation of Host Resistance against Bacterial Infection by Treatment with Leustroducsin B, a New CSF Inducer

Contact Info

Product

Resources

About